amifampridine phosphate · Catalyst Pharms · NDA 208078
Firdapse
Earliest generic entry, as listed
25 Feb 2037
Blocked by patent: US 10626088.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10626088 | drug product · sets the listed date | 25 Feb 2037 |
| US 10793893 | use U-2956 | 26 May 2034 |
| US 11060128 | use U-2956 | 29 Jun 2032 |
| US 11268128 | use U-2956 | 29 Jun 2032 |
| US 11274331 | use U-2956 | 29 Jun 2032 |
| US 11274332 | use U-2956 | 29 Jun 2032 |
Exclusivities · 1 unexpired
| ODE-553 | orphan drug (7 years) | 29 Sep 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208078 · 001 · RLD | tablet, oral | EQ 10MG BASE | 25 Feb 2037 |